Monday, May 16, 2022
12:18 PM EST – Revive Therapeutics Ltd : Provides an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. Revive Therapeutics Ltd (C.RVV) shares were up $0.08 at 0.3.
Stocks in Play: Revive Therapeutics Ltd, Mon, 16 May 2022 12:27:07 EST